United Biomedical Inc., based in Lake Success, N.Y., recently received approval from the U.S. Food and Drug Administration to market a new type of AIDS antibody screening and diagnostic test. The UBI-Olympus HIV-1 enzyme immunoassay (EIA) was jointly developed by United Biomedical Inc. and Olympus Inc. The UBI-Olympus test will be manufactured by UBI and marketed worldwide by Olympus Optical Co. Ltd. The new AIDS antibody test is based on I highly specific and conserved small peptide segments of the AIDS virus. Chemically synthesized peptides are used in the detection of antibodies to the AIDS virus. The new test is safer than other AIDS antibody screening and diagnostic tests, because the use of chemically synthesized peptides eliminates the need for growing the AIDS virus to obtain protein segments for antibody detection. In addition, the incidence of false-positive, or nonspecific, test results is minimized, because of the precise binding of the...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?